NECTIN4
Chr 1nectin cell adhesion molecule 4
Also known as: EDSS1, LNIR, PRR4, PVRL4, nectin-4
This gene encodes a member of the nectin family. The encoded protein contains two immunoglobulin-like (Ig-like) C2-type domains and one Ig-like V-type domain. It is involved in cell adhesion through trans-homophilic and -heterophilic interactions. It is a single-pass type I membrane protein. The soluble form is produced by proteolytic cleavage at the cell surface by the metalloproteinase ADAM17/TACE. The secreted form is found in both breast tumor cell lines and breast tumor patients. Mutations in this gene are the cause of ectodermal dysplasia-syndactyly syndrome type 1, an autosomal recessive disorder. Alternatively spliced transcript variants have been found but the full-length nature of the variant has not been determined.[provided by RefSeq, Jan 2011]
Primary Disease Associations & Inheritance
Clinical highlights
Some data sources returned errors (2)
gnomad: TimeoutError: The operation was aborted due to timeout
omim: Error: OMIM fetch failed: 429
Population Genetics & Constraint
Constraint data not available from gnomAD.
ClinVar Variant Classifications
0 submitted variants in ClinVar
Protein Context — Lollipop Plot
NECTIN4 · protein map & ClinVar variants
Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.
External Resources
Links to major genomics databases and tools
Clinical Trials
Active and recruiting trials from ClinicalTrials.gov
Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors
RECRUITINGPersonalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
RECRUITINGClinical Application of PET Imaging Targeting Nectin-4 in Malignant Tumors
NOT YET RECRUITINGA Study of AK146D1 for Injection in the Treatment of Advanced Solid Tumors
RECRUITINGAn Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
RECRUITINGSafety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
ACTIVE NOT RECRUITINGZelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
ACTIVE NOT RECRUITINGStudy of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer
RECRUITINGTarget-specific immunoPET Imaging of Digestive System Carcinoma
RECRUITINGA Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer
RECRUITINGTesting Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy
ACTIVE NOT RECRUITINGA Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
ENROLLING BY INVITATIONExternal Resources
Links to major genomics databases and tools